Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

SNY

Sanofi ADR

Jan 22 • 04:00PM ET

51.51

Dollar change -0.18
Percentage change -0.35	%

Healthcare • Drug Manufacturers - General • France • NASD

Peers: NVS PFE MRK GSK BMY LLY AZN JNJ ABBV AMGN

| Held by: FVD GCOW PVAL PPH PID AVDE APIE QQQJ BUSA GDIV

Scroll to Statements

Index	-	P/E	28.40	EPS (ttm)	1.81	Insider Own	0.00%	Shs Outstand	2.61B	Perf Week	6.32%
Market Cap	128.55B	Forward P/E	11.91	EPS next Y	4.33	Insider Trans	-	Shs Float	2.50B	Perf Month	9.57%
Income	4.56B	PEG	3.47	EPS next Q	0.74	Inst Own	11.31%	Short Float	0.17%	Perf Quarter	-6.23%
Sales	47.68B	P/S	2.70	EPS this Y	-11.82%	Inst Trans	0.49%	Short Ratio	1.74	Perf Half Y	0.88%
Book/sh	31.14	P/B	1.65	EPS next Y	11.73%	ROA	3.31%	Short Interest	4.21M	Perf Year	0.94%
Cash/sh	2.92	P/C	17.65	EPS next 5Y	8.18%	ROE	5.80%	52W Range	45.22 - 58.97	Perf YTD	6.80%
Dividend Est.	1.99 (3.86%)	P/FCF	21.82	EPS past 5Y	2.68%	ROI	4.89%	52W High	-12.65%	Beta	0.55
Dividend TTM	2.04 (3.95%)	Quick Ratio	0.65	Sales past 5Y	3.63%	Gross Margin	61.47%	52W Low	13.91%	ATR (14)	0.87
Dividend Ex-Date	May 09, 2024	Current Ratio	1.00	EPS Y/Y TTM	-49.09%	Oper. Margin	21.26%	RSI (14)	66.07	Volatility	1.49% 1.38%
Employees	87994	Debt/Eq	0.33	Sales Y/Y TTM	5.18%	Profit Margin	9.56%	Recom	1.74	Target Price	59.31
Option/Short	Yes / Yes	LT Debt/Eq	0.20	EPS Q/Q	-	Payout	63.38%	Rel Volume	0.76	Prev Close	51.69
Sales Surprise	3.35%	EPS Surprise	3.11%	Sales Q/Q	-	Earnings	Jan 30 BMO	Avg Volume	2.42M	Price	51.51
SMA20	4.86%	SMA50	5.78%	SMA200	0.99%	Trades		Volume	1,836,352	Change	-0.35%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-26-24	Reiterated	Argus	Buy	$55 → $60
Jan-23-24	Initiated	Morgan Stanley	Equal-Weight	$55
Jan-16-24	Resumed	UBS	Buy
Dec-05-23	Downgrade	JP Morgan	Overweight → Neutral
Oct-30-23	Downgrade	Stifel	Buy → Hold
Sep-06-23	Upgrade	Berenberg	Hold → Buy
Jul-14-23	Initiated	HSBC Securities	Buy
Apr-28-23	Downgrade	Deutsche Bank	Hold → Sell
Mar-27-23	Upgrade	Barclays	Equal Weight → Overweight
Dec-13-22	Resumed	Morgan Stanley	Overweight
Aug-12-22	Upgrade	Deutsche Bank	Sell → Hold
Aug-09-22	Downgrade	UBS	Buy → Neutral
May-23-22	Initiated	SVB Leerink	Outperform
Sep-27-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jan-15-21	Initiated	Deutsche Bank	Sell
Sep-29-20	Initiated	Berenberg	Hold
Mar-17-20	Upgrade	Barclays	Underweight → Equal Weight
Mar-11-20	Upgrade	Goldman	Neutral → Buy
Feb-11-20	Initiated	SVB Leerink	Mkt Perform
Jan-06-20	Upgrade	JP Morgan	Neutral → Overweight

Show Previous Ratings

Jan-22-25 05:15AM	FDA lifts hold on Opellas trial to support switch of Cialis to OTC drug (Clinical Trials Arena)
01:00AM	Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma (GlobeNewswire)
Jan-21-25 01:00AM	Press Release: Opella reaches study milestone for Cialis (GlobeNewswire)
Jan-20-25 12:59PM	SK bioscience and Sanofis GBP410 vaccine enters global Phase III trials (Clinical Trials Arena)
Jan-16-25 08:25AM	Sanofi to increase competition in atopic dermatitis market after Dupixent success (Clinical Trials Arena)
12:30PM	Loading…
Jan-15-25 12:30PM	Sanofi: Information concerning the total number of voting rights and shares November 2024 (GlobeNewswire)
Jan-13-25 01:00AM	Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma (GlobeNewswire)
Jan-11-25 10:55AM	IGM Biosciences downgraded to Hold from Buy at Jefferies (TipRanks)
Jan-10-25 05:26AM	Sanofi reports positive results from trial of multiple myeloma drug candidate (Clinical Trials Arena)
Jan-09-25 10:57AM	Sanofi's Blood Cancer Drug's New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma (Benzinga)
01:00AM	Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma (GlobeNewswire)
Jan-08-25 01:16PM	Sanofi taps Alloy Therapeutics for CNS antisense drug development (Pharmaceutical Technology)
Jan-07-25 06:00PM	Third Rock-backed Maze Therapeutics reveals profit in US IPO filing (Reuters)
Dec-31-24 07:05AM	Drugmakers to raise US prices on over 250 medicines starting Jan. 1 (Reuters)
Dec-26-24 06:01AM	Olympian Jordan Chiles is setting her sights on a new goal: raising awareness of type 1 diabetes (Fortune)
01:55PM	Loading…
Dec-23-24 01:55PM	Why Is Sanofi (SNY) Among the Best European Dividend Stocks To Buy Now? (Insider Monkey)
08:29AM	SK bioscience and Sanofi expand agreement for pneumococcal conjugate vaccines (Pharmaceutical Technology)
01:00AM	Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines (GlobeNewswire)
Dec-21-24 06:28AM	Sanofis Tolebrutinib Receives FDA Breakthrough Therapy Designation for nrSPMS (TipRanks)
Dec-20-24 05:25PM	Why Cytokinetics Stock Was a Nearly 5% Winner Today (Motley Fool)
Dec-19-24 12:00PM	Presse release: Jean-Paul Kress to join Sanofi's Board of Directors (GlobeNewswire)
Dec-18-24 06:33AM	Strength Seen in Sanofi (SNY): Can Its 6.7% Jump Turn into More Strength? (Zacks)
05:26AM	Sanofi and Tevas duvakitug meets primary endpoints in Phase IIb trial (Clinical Trials Arena)
Dec-17-24 06:06PM	Analyst Report: Sanofi (Morningstar Research) +6.65%
04:36PM	Teva and Sanofi jump on experimental bowel disease drug success (Yahoo Finance Video)
04:10PM	Teva Catapults 26%, Hitting A Six-Year High, After Scoring A Win With Sanofi-Tied Drug (Investor's Business Daily)
01:20PM	Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's (Investopedia)
12:00PM	Teva Stock Soars 19% as Game-Changing IBD Drug Duvakitug Crushes Trial Expectations (GuruFocus.com)
11:55AM	Teva Catapults 22%, Hitting A Five-Year High, After Scoring A Win With Sanofi-Tied Drug (Investor's Business Daily)
11:51AM	Teva, Cloudflare, Sanofi: Trending Tickers (Yahoo Finance Video)
11:51AM	Loading…
11:51AM	Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment (The Wall Street Journal)
10:37AM	Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug (Investor's Business Daily)
09:17AM	Teva Stock Soars on Early Bowel Disease Drug Data (Barrons.com)
09:17AM	Teva Shares Soar on Early Bowel Disease Drug Data (Barrons.com)
09:16AM	Why Are Teva And Sanofi Stocks Trading Higher On Tuesday? (Benzinga)
07:30AM	Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn's Disease (GlobeNewswire)
07:30AM	Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn's disease (GlobeNewswire)
05:59AM	Sanofi, Teva say study results show gut disease drug could be best in class (BioPharma Dive)
03:21AM	Sanofi sues HHS to defend 340B rebate policy (Healthcare Dive)
Dec-16-24 07:43AM	Sanofi's multiple sclerosis therapy gains breakthrough therapy status from FDA (Pharmaceutical Business Review)
Dec-13-24 09:59AM	Novavax Cut Its Outlook Despite Beating Third-Quarter Forecasts. Is It A Sell In December 2024? (Investor's Business Daily)
01:00AM	Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis (GlobeNewswire)
Dec-12-24 05:54PM	Gilead appoints Sanofi official Dietmar Berger as next chief medical officer (Reuters)
04:34AM	Sanofis combo vaccines gain FDA fast track designation (Pharmaceutical Technology)
Dec-11-24 01:00AM	Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US (GlobeNewswire)
Dec-10-24 10:33AM	RSV prophylactic market to reach $6.2bn in 8MM by 2030 (Pharmaceutical Technology)
Dec-09-24 02:06PM	Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients (GlobeNewswire)
07:21AM	Sanofis Phase III trial of rilzabrutinib for thrombocytopenia meets endpoint (Clinical Trials Arena)
Dec-07-24 11:30AM	Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP (GlobeNewswire)
Dec-06-24 01:30AM	Press Release: Availability of the revised financial statements for Sanofi excluding Opella (GlobeNewswire)
Dec-03-24 01:05PM	Trump 2.0 could see a rise in biopharmaceutical M&A deals (Pharmaceutical Technology)
04:30AM	China welcomes new US$1 billion Sanofi project in Beijing (South China Morning Post)
12:41AM	Sanofi to Invest $1.05 Billion in New Insulin Manufacturing Base in China (The Wall Street Journal)
Dec-02-24 07:49AM	Analyst Report: Sanofi (Morningstar Research)
06:35AM	Sanofi announces its biggest China investment deal amid China-EU trade tensions (Reuters)
Nov-30-24 11:27AM	Why Sanofi (SNY) Is One of the Best ADR Stocks to Invest in? (Insider Monkey)
Nov-29-24 01:00AM	Sanofis chief digital officer says remote work means employees lose the serendipity needed to innovate (Fortune)
Nov-27-24 05:45AM	Sanofi CEO Paul Hudson takes inspiration from Fight Club to get his team hooked on AI (Fortune)
Nov-26-24 04:03AM	Sanofi joins J&J, Eli Lilly in proposing 340B rebate model (Healthcare Dive)
Nov-25-24 08:41AM	Trumps presidency return: boom or bust for biopharmaceutical deal activity? (Pharmaceutical Technology)
Nov-22-24 12:32PM	Sanofi plans to change hospital drug-discount program (Reuters)
Nov-20-24 10:22AM	Heres What Drove Sanofis (SNY) Earnings (Insider Monkey)
08:11AM	Sanofi: Information concerning the total number of voting rights and shares - October 2024 (GlobeNewswire)
Nov-18-24 12:46AM	Analyst Report: Sanofi (Morningstar Research)
Nov-15-24 04:18PM	How analysts are reacting to RFK Jr. as Trump's HHS pick (Yahoo Finance Video)
12:40PM	FDA reviews Sanofi and Regenerons Dupixent label expansion for urticaria (Pharmaceutical Technology)
12:15PM	Stocks to Watch Friday: Applied Materials, Alibaba, Domino's, Novo Nordisk (The Wall Street Journal)
11:15AM	Trumps RFK Jr. Pick Weighs on Vaccine Makers (The Wall Street Journal)
09:43AM	Analysts think Wall Street's reaction to the RFK Jr. news is 'overdone.' Sort of. (Yahoo Finance)
07:00AM	FDA to review Sanofi, Regeneron's Dupixent sBLA for CSU (Pharmaceutical Business Review)
06:45AM	RFK Jr. News Hits Global Pharma Stocks (The Wall Street Journal)
05:19AM	European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department (The Wall Street Journal)
04:36AM	EMAs CHMP recommends Sanofis Sarclisa approval for multiple myeloma (Pharmaceutical Technology)
03:15AM	Drugmaker stocks slide as Trump picks vaccine sceptic RFK Jr for US health job (Reuters)
01:00AM	Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria (GlobeNewswire)
12:59AM	Dupixent (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU) (GlobeNewswire)
Nov-14-24 11:42AM	Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma (GlobeNewswire)
Nov-13-24 11:06AM	Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease (Benzinga)
02:08AM	Novavax Inc (NVAX) Q3 2024 Earnings Call Highlights: Strategic Partnerships and Financial ... (GuruFocus.com)
Nov-12-24 02:43PM	Novavax: Stock plunges after quarterly earnings, but sees hope in licensing deals (Yahoo Finance)
02:43PM	Novavax stock plunges after quarterly earnings, but company sees hope in licensing deals (Yahoo Finance)
08:05AM	Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales (Reuters)
Nov-11-24 06:00AM	Recordati SpA (RICFY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Nov-08-24 01:02PM	Is Novavax Stock A Sell After An Unexpected Side Effect Torpedoed Its Testing Plans? (Investor's Business Daily)
09:38AM	Analyst Report: Sanofi (Morningstar Research)
Nov-07-24 05:42AM	Advent Mulls 5 Billion Sale of Generic Drugmaker Zentiva (Bloomberg)
04:28AM	EMA approves Sanofi/Regenerons Dupixent for young EoE patients (Pharmaceutical Technology)
Nov-06-24 01:00AM	Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis (GlobeNewswire)
01:00AM	Dupixent (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis (GlobeNewswire)
Nov-01-24 05:01PM	Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ... (GuruFocus.com)
03:07AM	Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
Oct-30-24 12:14PM	Q3 2024 BioMarin Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
Oct-28-24 05:54PM	Beyfortus® immunization to protect infants from RSV has begun (PR Newswire)
Oct-26-24 03:04AM	Sanofi SA (SNY) Q3 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Advances (GuruFocus.com)
Oct-25-24 06:55PM	Analyst Report: Sanofi (Morningstar Research)
05:23PM	Why Sanofi Stock Flew Higher on Friday (Motley Fool)
04:24PM	Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat (Investor's Business Daily)
03:00PM	Sanofi (SNY) Q3 2024 Earnings Call Transcript (Motley Fool)
01:57PM	Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent (Benzinga)
12:21PM	Sanofi Shocks the Market: Massive Q3 Surge, Game-Changing Moves, and Bold Divestment Plans (GuruFocus.com)

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SNY

Sanofi ADR

Upgrade your FINVIZ experience